Leonid V. Shunyakov
Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Leonid V. Shunyakov

Oncology | Hematology | Hematology Oncology
Central Care Cancer Center
Central Care PA
1501 N Oakland Ave, 
Bolivar, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients

Distinguished in WT1-Related Wilms Tumor Syndromes
Central Care Cancer Center
Central Care PA
1501 N Oakland Ave, 
Bolivar, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Leonid Shunyakov is an Oncologist and a Hematologist in Bolivar, Missouri. Dr. Shunyakov is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Anal Cancer, Pleuropulmonary Blastoma, and Familial Colorectal Cancer. Dr. Shunyakov is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in KS
Hospital Affiliations
Mercy Hospital Springfield
Cox Medical Centers
Citizens Memorial Hospital
Languages Spoken
English
Russian
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Provider Partners Health Plan
  • MEDICARE SNP
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

CENTRAL CARE PA
1501 N Oakland Ave, Bolivar, MO 65613
Call: 417-326-7200

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


8 Clinical Trials

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
Enrollment Status: Recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Drug: ARX788
Study Phase: Phase 2
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 4
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion
Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion
Enrollment Status: Completed
Publish Date: September 10, 2022
Intervention Type: Drug
Study Drugs: Docetaxel+Plinabulin, Docetaxel
Study Phase: Phase 3
View 7 Less Clinical Trials

3 Total Publications

Rare presentation and unconventional treatment of Rosai-Dorfman disease.
Rare presentation and unconventional treatment of Rosai-Dorfman disease.
Journal: BMJ case reports
Published: October 01, 2024
View All 3 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jaswinder Singh
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jaswinder Singh
Hematology Oncology | Hematology | Oncology

Golden Valley Memorial Hospital District

1600 N 2nd St, 
Clinton, MO 
 (56.0 miles away)
660-885-5511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jaswinder Singh is a Hematologist Oncology specialist and a Hematologist in Clinton, Missouri. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Familial Colorectal Cancer, Familial Pancreatic Cancer, Pancreatic Cancer, Vitrectomy, and Bone Marrow Aspiration. Dr. Singh is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Lavanya B. Tiriveedhi
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Lavanya B. Tiriveedhi
Hematology Oncology | Hematology | Oncology

Mercy Clinic Springfield Communities

2055 S Fremont Ave, 
Springfield, MO 
 (32.2 miles away)
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Lavanya Tiriveedhi is a Hematologist Oncology specialist and a Hematologist in Springfield, Missouri. Dr. Tiriveedhi is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Richter Syndrome, and Chronic Lymphocytic Leukemia (CLL). Dr. Tiriveedhi is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Jessica N. Snider
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Jessica N. Snider
Hematology Oncology | Hematology | Oncology

Mercy Clinic Springfield Communities

2115 S Fremont Ave, 3100 Mc Lab And Imaging Serv, 
Springfield, MO 
 (32.2 miles away)
417-820-3738
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jessica Snider is a Hematologist Oncology specialist and a Hematologist in Springfield, Missouri. Dr. Snider is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Paget Disease of the Breast, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Snider is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shunyakov's expertise for a condition
ConditionClose
    • Distinguished
    • Agranulocytosis
      Dr. Shunyakov is
      Distinguished
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Anal Cancer
      Dr. Shunyakov is
      Distinguished
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Breast Cancer
      Dr. Shunyakov is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Chromophobe Renal Cell Carcinoma
      Dr. Shunyakov is
      Distinguished
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    • Chronic B-Cell Leukemia (CBCL)
      Dr. Shunyakov is
      Distinguished
      . Learn about Chronic B-Cell Leukemia (CBCL).
      See more Chronic B-Cell Leukemia (CBCL) experts
    • Chronic Familial Neutropenia
      Dr. Shunyakov is
      Distinguished
      . Learn about Chronic Familial Neutropenia.
      See more Chronic Familial Neutropenia experts
    View All 24 Distinguished Conditions
    • Advanced
    • Acute Mountain Sickness
      Dr. Shunyakov is
      Advanced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Adult Immune Thrombocytopenia
      Dr. Shunyakov is
      Advanced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Adult Soft Tissue Sarcoma
      Dr. Shunyakov is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Shunyakov is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Anemia
      Dr. Shunyakov is
      Advanced
      . Learn about Anemia.
      See more Anemia experts
    • Appendix Cancer
      Dr. Shunyakov is
      Advanced
      . Learn about Appendix Cancer.
      See more Appendix Cancer experts
    View All 60 Advanced Conditions
    • Experienced
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Shunyakov is
      Experienced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • Acute Eosinophilic Pneumonia
      Dr. Shunyakov is
      Experienced
      . Learn about Acute Eosinophilic Pneumonia.
      See more Acute Eosinophilic Pneumonia experts
    • Acute Monoblastic Leukemia (AmoL)
      Dr. Shunyakov is
      Experienced
      . Learn about Acute Monoblastic Leukemia (AmoL).
      See more Acute Monoblastic Leukemia (AmoL) experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Shunyakov is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Shunyakov is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Shunyakov is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    View All 158 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved